Umberto Malapelle
Jan 7, 2025, 14:18
ctDNA and Beyond to Serve Immunotherapy Key Insights from ESMOImmuno24 – International Society of Liquid Biopsy
International Society of Liquid Biopsy shared a post on X:
“ISLB Research Highlight! ctDNA and Beyond to Serve Immunotherapy.
Key Insights from ESMOImmuno24:
- Stable blood DNA methylation profiles may serve as reliable biomarkers in NSCLC (Abstract 24P).
- Increased somatic mutation rates and NLR values correlate with disease progression in ICI-treated NSCLC (Abstract 28P).
- ctDNA levels predict survival outcomes in metastatic uveal melanoma (Abstract 25P).
- Peripheral immune cell analysis may improve response prediction for PD-1 inhibitors in head and neck cancers (Abstract 27P).
- Changes in neutrophil/CD4+ T cell balance linked to immune-related adverse events (irAEs) (Abstract 37P).
Liquid biopsy is redefining immuno-oncology, but prospective trials are needed!
Read the analysis by our esteemed Professor Umberto Malapelle based on recent results presented during ESMOImmuno2024.”
More posts featuring International Society of Liquid Biopsy.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 7, 2025, 14:09
Jan 7, 2025, 13:39
Jan 7, 2025, 13:33
Jan 7, 2025, 13:15
Jan 7, 2025, 12:52
Jan 7, 2025, 12:44
Jan 7, 2025, 12:38